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ABSTRACT 1 
 2 
The methanol/water and particularly the water extracts obtained from 26 mushroom species 3 
were able to inhibit the 3-hydroxy-3-methyl-glutaryl CoA reductase (HMGCR) activity to 4 
different extent (10 to 76%). Cultivated mushrooms such as Pleurotus sp. and Lentinula 5 
edodes were among the strains which showed higher HMGCR inhibitory capacities. Their 6 
inhibitory properties were not largely influenced by cultivation parameters, mushroom 7 
developmental stage or flush number. The HMGCR inhibitory activity of L. edodes was 8 
concentrated in the cap excluding the gills while in P. ostreatus it was distributed through all 9 
the different tissues. A method to obtain aqueous fractions with high HMGCR inhibitory 10 
activity was optimized using an accelerated solvent extractor (ASE) by selecting 10.7 MPa 11 
and 25ºC as common extraction conditions and 5 cycles of 5 min each for P. ostreatus fruiting 12 
bodies and 15 cycles of 5 min for L. edodes suggesting that the potential HMGCR inhibitors 13 
are different in the two selected mushrooms. 14 
 15 
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1. INTRODUCTION 1 
Coronary heart disease (CHD) is the leading cause of death in the Western world after cancer 2 
according to the World Health Organization. Many studies have established that high total-3 
cholesterol and low-density lipoprotein (LDL) cholesterol levels are risk factors for CHD and 4 
mortality. Several in vivo studies have demonstrated the ability of certain edible mushrooms 5 
to lower cholesterol levels in serum. Species such as Pleurotus spp. (Opletal et al., 1997; 6 
Bajaj et al., 1997; Bobek&Galbavy, 1999; Schneider et al., 2011), Agaricus bisporus (Jeong 7 
et al., 2011), Ganoderma lucidum (Berger et al., 2004), Lentinula edodes, Grifola frondosa, 8 
Flammulina velutipes (Fukushima et al., 2001), Auricularia auricular and Tremella 9 
fuciformis (Cheung, 1996), among others (Roupas et al., 2012), have been investigated in 10 
animals and human studies. 11 
Apparently, the hypocholesterolemic effect of the mushroom fruiting bodies and several types 12 
of their extracts is reached by different mechanisms of action such as impairing dietary 13 
cholesterol absorption or inhibiting the endogenous cholesterol metabolism (Guillamón et al., 14 
2010). Mushrooms are rich in chitin (dietary fibre) and specific -glucans which might inhibit 15 
cholesterol absorption by increasing the faecal excretion of bile acids and reducing the 16 
amount of serum LDL-cholesterol (Guillamón et al., 2010; Chen & Seviour, 2007). 17 
Eritadenine (an adenosine analogue alkaloid) is another compound isolated from Lentinula 18 
edodes (shiitake mushroom) which is able to lower cholesterol levels. This molecule inhibits 19 
S-adenosylhomocysteine hydrolase and modifies the hepatic phospholipid metabolism 20 
(Chibata et al., 1969, Sugiyama et al., 1995, Yamada et al., 2007).   21 
According to previous reports, oyster mushrooms (Pleurotus spp.) contained lovastatin, a 22 
compound able to lower cholesterol levels inhibiting 3-hydroxy-3-methyl-glutaryl CoA 23 
reductase (HMGCR) (Gunde-Cimerman et al., 1993; Gunde-Cimerman&Cimerman, 1995), 24 
the key-enzyme in the cholesterol metabolism. Statins are the most potent drugs available for 25 
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reducing plasma low density lipoproteins (LDL) in cholesterol concentrations (Shitara& 1 
Sugiyama, 2006). However, other reports found no detectable statins levels in Pleurotus sp. 2 
fruiting bodies although high HMGCR inhibition activities were recorded (Schneider et al., 3 
2010; Gil-Ramirez et al., 2011). Other compounds (obtained from Ganoderma lucidum) were 4 
also described as being able to impair the proper function of the enzyme (Berger et al., 2004). 5 
Thus, in this work a preliminary screening of HMGCR inhibitors was carried out using 6 
several edible mushroom species and varieties. The screening was also performed in 7 
cultivated mushrooms harvested from cultivation rooms with different cultivation parameters 8 
in an attempt to define the conditions required for the synthesis of the effective inhibitors. 9 
Once the mushrooms varieties containing higher HMGCR inhibitory activity were defined, 10 
they were submitted to pressurized solvent extractions (or accelerated solvent extractions, 11 
ASE) in order to optimize environmentally friendly and GRAS methods able to obtain fungal 12 
fractions with high HMGCR inhibitory activity to further functionalize foods with potentially 13 
hypocholesterolemic properties (Chen et al., 2011). 14 
 15 
2. MATERIAL AND METHODS 16 
2.1 Biological material and samples preparation 17 
Mushroom strains used in this investigation were Lentinus edodes S. (Berkeley), Cantharellus 18 
cibarius (Fr.), Lactarius deliciosus (Fr.), Boletus edulis (Bull. Ex Fr.), Pleurotus ostreatus 19 
(Jacq.Ex Fr.) Kummer, Agaricus bisporus L. (Imbach), Amanita caesarea (Scop. Ex Fri.) 20 
Pers. Ex Schw., Morchella esculenta (Pers Ex Amans), Agaricus blazei Murill ss. (Heinem), 21 
Grifola frondosa (Dicks.) Gray, Ganoderma lucidum (Curtis) P.Karst., Flammulina velutipes 22 
(Curt. Ex Fr.) Singer, Pleurotus eryngii (D.C. Ex Fr.) Quel, Lyophyllum shimeji (Kawam.), 23 
Morchella conica (Pers.), Agrocybe aegerita (Briganti) Singer, Auricularia judea (Bull. Ex 24 
St.Amans) Berck, Amanita ponderosa Malençon & R. Heim, Craterellus cornucopioides (L. 25 
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Ex Fr.) Pers, Marasmius oreades (Bolt. Ex Fr.) Fr., Lepiota procera (Scop. Ex Fr.) Singer., 1 
Pholiota nameko (T. Itô) S. Imai, Calocybe gambosa (Fr.) Donk, Hydnum repandum (Linné 2 
Ex Fr.), Cantharellus lutescens (Pers.), Pleurotus pulmonarius (Fr.) Quel. 3 
Fruiting bodies from wild mushrooms were purchased from a local market in Madrid (Spain). 4 
The cultivable strains were grown in cultivation rooms with automatic control of cultivation 5 
parameters (temperature, R.H., CO2) at CTICH (Centro Tecnológico de Investigación del 6 
Champiñón de La Rioja, Autol, Spain) or at the cultivation facilities of some mushroom 7 
growers belonging to the La Rioja´s mushroom association using commercially available 8 
substrates depending on the mushroom specie to cultivate. Fruiting bodies were harvested at 9 
the usual developmental stage prior to commercialization except in those experiments when 10 
the effect of the developmental stage was studied. The recorded parameters are described in 11 
Table 1. 12 
Complete fruiting bodies or their separated tissues were immediately frozen, freeze-dried, 13 
ground and sieved until the particle size smaller than 0.3 mm as described in Ramirez-14 
Anguiano et al. (2007) and stored at -20ºC until further use.  15 
To extract the potential inhibitors from the spores allowing the breaking down of the spore 16 
walls, they were first treated with methanol as described by Gunde-Cimerman et al. (1993). 17 
 18 
2.2 Determination of HMGCoA-red inhibitors in mushrooms 19 
Mushroom powders (50 mg/ml) were mixed with water, methanol/water (1:1 v/v) or 20 
methanol. Suspensions were shaken in a Vortex for 1 min and centrifuged at 12000 rpm 21 
(8,854 x g) for 2min (Eppendorf mini-spin, Madrid, Spain) according to the user´s manual. 22 
Supernatants were used as source of HMGCR inhibitors. 23 
HMGCR activity was measured using the commercial HMG-CoA Reductase Assay (Sigma, 24 
Madrid) according to the user´s manual. The assay is based on the spectrophotometric 25 
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measurement of the decrease in absorbance at 340 nm, which represents the oxidation of 1 
NADPH by the catalytic subunit of HMGCR in the presence of the substrate HMG-CoA 2 
according to the reaction: 3 
HMG-CoA + 2NADPH + 2H
+ mevalonate + 2NADP+ + CoA-SH 4 
Mushroom supernatants (20 l) were applied into a 96 wells-plate and their absorbance 5 
change was monitorized at 37ºC using a microplate reader (Tecan Group Lt, Männedorf, 6 
Switzerland). 7 
Pravastatin was utilized as a control for positive inhibition. Other control samples were 8 
prepared in each assay by substituting the mushroom extract by the same solvent solution 9 
utilized in the extract. These controls were considered as 100% activity and tested samples 10 
were referred to them as percentage of inhibition or activity. Assays were performed in 11 
duplicate. 12 
 13 
2.3 Pressurized water extractions to obtain fractions with HMGCR inhibitory activity 14 
Mushroom powders (1g) were mixed with sea sand (Sigma, Madrid, Spain) (4g) and 15 
submitted to pressurized solvent extraction at 1500 psi (10.68 MPa) using an accelerated 16 
solvent extractor (ASE) (Dionex, ASE 350, Sunnyvale, CA, USA). Several parameters such 17 
as extraction time or cycles number and temperature were changed in order to optimize the 18 
extraction method to obtain fractions with high HMGCR inhibitory activity.  19 
Obtained fractions were immediately frozen, lyophilized and stored at -18ºC until further 20 
analysis. Extracted dry matter content was measured to calculate the extraction yields.  21 
 22 
2.4 Statistical analysis 23 
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One way analysis of variance (ANOVA) was performed using a Statgraphics® Plus 3.1 for 1 
Windows software (Statistical Graphics Corporation, Rockville, MD, USA). The mean 2 
comparison test used was Fisher’s least significant differences procedure (LSD). 3 
 4 
3. RESULTS AND DISCUSSION 5 
3.1 Screening of mushrooms species as a source of HMGCR inhibitors 6 
Several wild and cultivated mushroom species were submitted to water and methanol/water 7 
(1:1, v/v) extraction since both type of solvents were previously described as able to extract 8 
compounds with HMGCR inhibitory activity (Gil-Ramírez et al., 2011). Methanol was also 9 
tested with a few strains but no interesting HMGCR inhibitory activity was found in any of 10 
the selected samples. Results indicated a wide variability within the different mushroom 11 
species (Figure 1). The water extracts of 8 species showed no significant HMGCR inhibitory 12 
activity and many showed inhibitory activities from 10 to 50%. However, strains such as 13 
Pleurotus sp., Cratharellus cornucopiodes, Amanita ponderosa and particularly Lentinula 14 
edodes showed inhibitory capacities ranging from 52 up to 76%. In most of the cases except 15 
for Agaricus bisporus and Cantharellus lutescens, the water extracts showed higher inhibitory 16 
activity than the methanol/water extracts. Surprisingly, A. bisporus methanol/water extracts 17 
showed almost 2 fold more capacity than the water extracts. 18 
No similar distribution was found between genera belonging to the same family, for instance, 19 
within the Pleurotaceae family (P. ostreatus, P. pulmonarius and P. eryngii) two species 20 
showed similar and high HMGCR inhibitory capacities but P. eryngii showed only 20.7% 21 
inhibitory capacity. On the contrary, the Agaricaceae family included two species (A. 22 
bisporus and A. blazeii) with low inhibition in their water extracts while L. procera was able 23 
to inhibit almost 50% of the enzyme. The Cantharellaceae family (C. lutescens, C. Cibarius 24 
and C. cornucopioides) as well as other families such as Marasmiaceae (M.oreades and L. 25 
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edodes), Morchellaceae (M. conica and M. esculenta) and Amanitaceae (A. caesarea and A. 1 
ponderosa) included species with no, middle and high inhibitory capacities. 2 
 3 
3.2 Influence of the cultivation parameters on the HMGCR inhibitory activity of 4 
cultivated mushrooms 5 
The water extracts from cultivated mushrooms such as Pleurotus sp. and L. edodes showed 6 
very interesting inhibitory activities and their growth can be more easily controlled than wild 7 
mushrooms. Environmental parameters usually influence the presence/absence of many 8 
compounds therefore; a more detailed study was carried out in those cultivated mushrooms in 9 
order to determine the effect of the cultivation parameters in their HMGCR inhibitory 10 
activities. 11 
Substrates were inoculated with commercial spawns from several P. ostreatus and L. edodes 12 
varieties in a minimum of three independent trials but performed under similar conditions. 13 
After cultivation, the obtained fruiting bodies from the first flush were harvested and their 14 
water extracts analyzed. Results showed no significant differences between Fungisem K15 15 
and Sylvan HK35 but they were significantly higher in Fungisem K15 than the other analyzed 16 
varieties (Figure 2a). Similar results were obtained when the different L. edodes spawns were 17 
studied (Figure 2b); significant differences were found between Sylvan 4312 and Mycelia 18 
3710 or Le Lion L8 but the standard deviation observed within similar trials suggested that 19 
other parameters different than variety are involved in the HMGCR inhibitory activity 20 
observed. 21 
Therefore, other parameters were investigated such as mushroom grower, automatic control of 22 
cultivation conditions (or traditional cultivation system), presence of bacterial blotch 23 
infection, pests (flies, mosquitoes etc.), good or poor quality fruiting bodies or mushroom 24 
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picked from places close to a Trichoderma sp. spot. However, no correlation was found 1 
within the detected HMGCR inhibitory activities and any of the indicated parameters. 2 
 3 
3.3 Developmental and tissue distribution of the HMGCR inhibitory activity of 4 
cultivated mushrooms 5 
P. ostreatus and L. edodes fruiting bodies from the same cultivation trial were harvested at 6 
different developmental stages including from primordia until cap was open and gills exposed 7 
(mature). The harvesting was repeated in the second and third flush. No significant 8 
differences were observed between flushes or developmental stages in the HMGCR inhibitory 9 
activity of the water extracts obtained from P. ostreatus mushrooms. In L. edodes mushrooms 10 
a slight decrease of the inhibitory capacity was observed with the increase of the flush number 11 
but no significant differences were found between young or mature fruiting bodies. This 12 
suggest that the compounds responsible for the HMGCR inhibitory activity are present 13 
through the whole sporophore life cycle and that they might be different between the two 14 
studied mushroom strains. This view was further supported by the fact that compounds 15 
potentially responsible for the inhibitory activity showed a different tissue distribution within 16 
the fruiting bodies. The water extracts obtained from different tissues of P. ostreatus showed 17 
similar HMGCR inhibitory activity indicating a homogeneous distribution (Figure 3a) thought 18 
the whole body while in the selected L. edodes variety the inhibitory activity was 19 
concentrated in the dermis and epidermis excluding the gills and the stipe (Figure 3b).  20 
Worth to take into consideration was the HMGCR inhibitory activity levels found in the 21 
discarded parts of the stipes, this part correspond to the lower stipe which is bound to the 22 
mycelium and the substrate, at the base of the fruiting body. Usually, this part of the 23 
mushroom is cut during harvesting because it might contain traces of substrate or it is 24 
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deformed and not commercialized. The HMGCR inhibition values of the discarded by-1 
product obtained from L. edodes varied depending on the strain since Amycell 4012 showed 2 
no HMGCR inhibitory activity but Sylvan 4312 showed a 37.1% inhibition, higher values 3 
than the 10.8% inhibition found in the discarded stipe of P. ostreatus. 4 
 5 
3.4 Pressurized water extraction of the cultivated mushrooms to obtain fractions with 6 
HMGCR inhibitory activity 7 
Pressurized water extractions are economically sustainable processes that are increasingly 8 
being developed as a response to the demand (by the food and other industries) of 9 
environmentally clean extraction processes to produce new extracts or compounds with a 10 
potential use as functional ingredients or nutraceuticals (Sun et al., 2012). Water is a non-11 
toxic and naturally occurring solvent that can replace organic solvents when used at higher 12 
temperatures and pressures. Accelerated solvent extraction using water has been used to 13 
extract i.e. polysaccharides with different structures and biological activities from edible 14 
mushrooms (Lo et al., 2007; Di et al., 2003) and they are, at the present, being scaled up for 15 
industrial applications (Pronyk & Mazza 2009).  16 
P. ostreatus and L. edodes fruiting bodies were submitted to extraction with pressurized water 17 
in order to obtain mushroom extracts with high HMGCR inhibitory activity to be in the future 18 
potentially used as hypocholesterolemic ingredient to functionalize foods. Thus, several 19 
parameters such as extraction temperature, time and cycles number were changed in order to 20 
optimize the extraction method. 21 
A range of temperatures was studied from 25 up to 200ºC and the obtained dry matter 22 
increased largely with the temperature, being 200ºC the best condition to extract almost 60 23 
and 80% of the material from P. ostreatus and L. edodes, respectively (Figure 4a). However, 24 
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when the HMGCR inhibitory capacity of the extracted fractions was measured, the increase of 1 
temperature was detrimental suggesting that the compounds responsible for the inhibition 2 
were thermolabile (Figure 4b). No significant differences were found between extractions at 3 
25 or 50ºC in both mushroom strains neither between these extractions from L. edodes and 4 
extractions with plain water however, water extraction of P. ostreatus showed a significantly 5 
higher inhibitory activity (80.1%) than its ASE extractions. Thus, extraction temperature was 6 
fixed at 25ºC and other ASE parameters were modified in order to improve extraction yields 7 
and inhibitory activities. 8 
Extractions carried out by selecting 5 cycles of 1 min each yielded almost half of the dry 9 
matter than longer extraction times from P. ostreatus mushrooms however, no significant 10 
differences were observed for L. edodes within 1 to 10 min; apparently all the water soluble 11 
compounds at 25ºC are easily extracted after 5 cycles of 5 min from both strains (Figure 5a). 12 
The ASE extracts obtained from both mushroom strains after 5 cycles of 1 to 10 min each 13 
showed high HMGCR inhibitory capacity while longer extractions showed a slightly lower 14 
inhibitory activity, suggesting than the compounds potentially responsible for the inhibition 15 
might be unstable if extracted for 75 min total extraction time (Figure 5b). The P. ostreatus 16 
extract obtained after 5 cycles of 1 min showed similar inhibitory capacity than longer 17 
extraction times, however, less dry matter was obtained pointing the 5 min extraction as the 18 
best extraction time, thus, the optimal number of cycles was further studied. 19 
Increase of the extraction cycles (of 5 min each at 25ºC) from 1 to 15 cycles increased the 20 
extracts yields almost 3 fold for both mushroom strains (Figure 6a). However, for P. 21 
ostreatus, the ASE extracts obtained after 5 cycles showed the highest inhibitory activity 22 
while no significant differences were observed within the HMGCR inhibitory capacity of all 23 
the ASE extracts from L. edodes obtained independently of the number of cycles (Figure 6b). 24 
These results suggested once more that the compounds responsible of the inhibitory capacity 25 
12 
 
might be different in both mushrooms since 5 cycles should be the optimal to extract the 1 
potentially enzyme inhibitors from P. ostreatus while higher cycles number can be used to 2 
extract higher amount of L. edodes extracts. But, both inhibitors are easily extracted with 3 
water and their HMGCR inhibitory activity is eliminated at temperatures where the typical 4 
protein denaturalization takes place suggesting that they might share similar chemical nature 5 
and it could include a proteic part in its structure. Actually, preliminary studies are being 6 
carried out suggesting that the inhibitors might be proteoglucans.  7 
4. CONCLUSION 8 
Several wild and cultivated mushroom species contain water soluble compounds potentially 9 
capable of inhibiting the key enzyme of the cholesterol metabolism using in vitro test. Two of 10 
the cultivated strains, Oyster and Shiitake mushrooms, were particularly interesting. Their 11 
higher or lower inhibitory capacity was probably dependent on specific requirements since no 12 
specific influence of the commercial variety, cultivation parameters or developmental stage of 13 
the mushroom was observed. Tissue distribution within the fruiting bodies was different 14 
suggesting the presence of different compounds with HMGCR inhibitory activity in both 15 
species. The potential inhibitory compounds could be easily extracted by using pressurized 16 
water extractions at 10.68 MPa and 25ºC, 5cycles of 5 min for P. ostreatus and up to 15 17 
cycles of 5 min for L. edodes. Thus, by using the optimized extraction methods, higher 18 
quantities of the potential inhibitors in will be extracted for further identification of the 19 
responsible compounds. The purification steps will have to be separately carried out for each 20 
mushroom since the responsible compounds might be different.   21 
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Table 1 Cultivation parameters recorded and correlated with the HMGCR inhibitory activity 1 
values obtained within the analyzed samples (P. ostreatus and L. edodes). 2 
Parameter Different type of samples 
Commercial spawn 
5 different commercial varieties per specie:  
P. ostreatus K15 Fungisem, HK35 Sylvean, K40 
Fungisem, S-300 Mispaj and H9 Gurelan and L. 
edodes4312 Sylvan, S05 Mispaj, 3710 Mycelia, Le 
Lion L8 and 4012 Amycel. 
Substrate 
Pasteurized straw (for P. ostreatus) and 
sterilized/pasteurized sawdust (for L. edodes) 
Disease influence Healthy, brown blotch, thrichoderma, pests 
Developmental stage Primordia, small, medium, large 
Flush number First, second, third and fourth flush 
Mushroom growers CTICH and 12 mushroom growers 
Modern controlled chambers Yes/No 
  3 
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Legends of the figures: 1 
Figure 1: HMGCR inhibitory activities of several mushrooms extracts obtained in water or 2 
methanol/water (1:1, v/v). 3 
 4 
Figure 2: HMGCR inhibitory activities of water extracts from the fruiting bodies obtained by 5 
cultivating different commercial spawns from a) Pleurotus ostreatus and b) Lentinula edodes. 6 
 7 
Figure 3: HMGCR inhibitory activities of water extracts from different tissues from fruiting 8 
bodies from the first flush of a) Pleurotus ostreatus Sylvan HK35 and b) Lentinula edodes 9 
Amycell 4012. 10 
 11 
Figure 4: a) ASE extraction yield and b) HMGCR inhibitory activities of Pleurotus ostreatus 12 
and Lentinula edodes fractions obtained after 5 cycles of 5 min each at different temperatures. 13 
 14 
Figure5: a) ASE extraction yield and b) HMGCR inhibitory activities of Pleurotus ostreatus 15 
and Lentinula edodes fractions obtained at 25ºC but at different extraction times per cycle (5 16 
cycles). 17 
 18 
Figure6: a) ASE extraction yield and b) HMGCR inhibitory activities of Pleurotus ostreatus 19 
and Lentinula edodes fractions obtained at 25ºC but after a different number of cycles (5 min 20 
each). 21 
22 
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Figure5: 1 
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Figure6: 1 
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